Drug
PF 08154225
PF 08154225: highest development phase Phase 1/2, developed by Pfizer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Pfizer
Trials
| Drug | Phase | Indication |
|---|---|---|
| PF-08154225 NCT07782450 | Phase 1/2 | Systemic Lupus Erythematosus |
Latest
No recent events.
Follow PF 08154225 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.